INTENSIVE EARLY TREATMENT DOESN'T HELP BLADDER CANCER SURVIVAL

The study appears in the April 7 online issue of the Journal of the National Cancer Institute. The findings need to be
interpreted with caution, Dr. Gary H. Lyman and colleagues at Duke University School of Medicine in Durham, N.C.,
wrote in an accompanying editorial. "The apparent association between provider treatment intensity defined as greater
average bladder cancer expenditures and worse bladder cancer-specific but not overall survival is more likely the result
of confounding by unavailable prognostic factors than the result of adverse events resulting from the procedures
themselves," Lyman and colleagues noted.

The study appears in the April 7 online issue of the Journal of the National Cancer Institute. The findings need to be

interpreted with caution, Dr. Gary H. Lyman and colleagues at Duke University School of Medicine in Durham, N.C., wrote

in an accompanying editorial. "The apparent association between provider treatment intensity defined as greater average

bladder cancer expenditures and worse bladder cancer-specific but not overall survival is more likely the result of

confounding by unavailable prognostic factors than the result of adverse events resulting from the procedures themselves,"

Lyman and colleagues noted.

The study appears in the April 7 online issue of the Journal of the National Cancer Institute. The findings need to be
interpreted with caution, Dr. Gary H. Lyman and colleagues at Duke University School of Medicine in Durham, N.C.,
wrote in an accompanying editorial. "The apparent association between provider treatment intensity defined as greater
average bladder cancer expenditures and worse bladder cancer-specific but not overall survival is more likely the result
of confounding by unavailable prognostic factors than the result of adverse events resulting from the procedures
themselves," Lyman and colleagues noted

The study appears in the April 7 online issue of the Journal of the National Cancer Institute. The findings need to be
interpreted with caution, Dr. Gary H. Lyman and colleagues at Duke University School of Medicine in Durham, N.C.,
wrote in an accompanying editorial. "The apparent association between provider treatment intensity defined as greater
average bladder cancer expenditures and worse bladder cancer-specific but not overall survival is more likely the result
of confounding by unavailable prognostic factors than the result of adverse events resulting from the procedures
themselves," Lyman and colleagues noted